Literature DB >> 26821108

Timeliness of lung cancer care in Victoria: a retrospective cohort study.

Sue M Evans1, Arul Earnest2, Wendy Bower2, Meera Senthuren3, Peta McLaughlin2, Rob Stirling2.   

Abstract

OBJECTIVE: To assess factors associated with second-line delays in the management of patients diagnosed with lung cancer. DESIGN, SETTING AND PARTICIPANTS: A retrospective cohort study, conducted in six public and two private Victorian hospitals, of 1417 patients aged 18 years or more who were diagnosed between July 2011 and October 2014 with an incident case of lung cancer identified by International Classification of Diseases, 10th revision codes (C34.0-C34.9, Z85.1, Z85.2) on the basis of either a clinical or pathological diagnosis. OUTCOME MEASURES: Time intervals between referral, diagnosis and initial definitive management.
RESULTS: The median time from referral to diagnosis was 15 days (interquartile range [IQR], 5-36); from diagnosis to initial definitive management, 30 days (IQR, 6-84); and from referral to initial definitive management, 53 days (IQR, 25-106). Factors that were significantly associated with delay between referral and initial definitive management include declining or not being referred to palliative care (hazard ratio [HR], v patients referred for palliation, 0.73; 95% CI, 0.62-0.86; P < 0.001), and being treated in a public hospital (HR, v patients managed in a private hospital, 0.55; 95% CI, 0.48-0.64; P < 0.001). The median time from referral to initial definitive management in public and private hospitals was 61 days (IQR, 35-118) and 30 days (IQR, 13-76) respectively; 48% of patients in public hospitals waited longer than the British National Health Service target of a maximum 62 days between referral and first definitive treatment.
CONCLUSION: There are significant delays at various stages of the patient journey after referral for initial definitive management. Having a greater understanding of these delays will enable strategies to be developed that improve the timeliness of care for patients with lung cancer.

Entities:  

Mesh:

Year:  2016        PMID: 26821108     DOI: 10.5694/mja15.01026

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  10 in total

1.  Lung cancer care trajectory at a Canadian centre: an evaluation of how wait times affect clinical outcomes.

Authors:  G Kasymjanova; D Small; V Cohen; R T Jagoe; G Batist; W Sateren; P Ernst; C Pepe; L Sakr; J Agulnik
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

2.  Timeliness of Care and Lung Cancer Tumor-Stage Progression: How Long Can We Wait?

Authors:  Amelia W Maiga; Stephen A Deppen; Rhonda Pinkerman; Carol Callaway-Lane; Pierre P Massion; Robert S Dittus; Eric S Lambright; Jonathan C Nesbitt; David Baker; Eric L Grogan
Journal:  Ann Thorac Surg       Date:  2017-10-21       Impact factor: 4.330

Review 3.  Defining timeliness in care for patients with lung cancer: a scoping review.

Authors:  Adnan Ansar; Virginia Lewis; Christine Faye McDonald; Chaojie Liu; Muhammad Aziz Rahman
Journal:  BMJ Open       Date:  2022-04-07       Impact factor: 2.692

4.  Pathways to diagnosis of non-small cell lung cancer: a descriptive cohort study.

Authors:  Stuart Purdie; Nicola Creighton; Kahren Maree White; Deborah Baker; Dan Ewald; Chee Khoon Lee; Alison Lyon; Johnathan Man; David Michail; Alexis Andrew Miller; Lawrence Tan; David Currow; Jane M Young
Journal:  NPJ Prim Care Respir Med       Date:  2019-02-08       Impact factor: 2.871

5.  Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP).

Authors:  Usha Menon; Peter Vedsted; David Weller; Alina Zalounina Falborg; Henry Jensen; Samantha Harrison; Irene Reguilon; Andriana Barisic; Rebecca J Bergin; David H Brewster; John Butler; Odd Terje Brustugun; Oliver Bucher; Victoria Cairnduff; Anna Gavin; Eva Grunfeld; Elizabeth Harland; Jatinderpal Kalsi; Anne Kari Knudsen; Mats Lambe; Rebecca-Jane Law; Yulan Lin; Martin Malmberg; Donna Turner; Richard D Neal; Victoria White
Journal:  BMJ Open       Date:  2019-11-27       Impact factor: 2.692

6.  Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: a national cohort study in Taiwan.

Authors:  Pei-Tseng Kung; Wen-Chen Tsai; Chang-Hung Tsai; Wei-Yin Kuo
Journal:  BMJ Open       Date:  2020-04-22       Impact factor: 2.692

7.  Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry: a protocol paper.

Authors:  Shantelle Smith; Margaret Brand; Susan Harden; Lisa Briggs; Lillian Leigh; Fraser Brims; Mark Brooke; Vanessa N Brunelli; Collin Chia; Paul Dawkins; Ross Lawrenson; Mary Duffy; Sue Evans; Tracy Leong; Henry Marshall; Dainik Patel; Nick Pavlakis; Jennifer Philip; Nicole Rankin; Nimit Singhal; Emily Stone; Rebecca Tay; Shalini Vinod; Morgan Windsor; Gavin M Wright; David Leong; John Zalcberg; Rob G Stirling
Journal:  BMJ Open       Date:  2022-08-29       Impact factor: 3.006

8.  Reasons for lack of referral to medical oncology for systemic therapy in stage IV non-small-cell lung cancer: comparison of 2003-2006 with 2010-2011.

Authors:  J J Ko; R Tudor; H Li; M Liu; K Skolnik; W Kells Boland; J Macklow; D Morris; D G Bebb
Journal:  Curr Oncol       Date:  2017-12-20       Impact factor: 3.677

9.  The LEAD study protocol: a mixed-method cohort study evaluating the lung cancer diagnostic and pre-treatment pathways of patients from Culturally and Linguistically Diverse (CALD) backgrounds compared to patients from Anglo-Australian backgrounds.

Authors:  Danielle Mazza; Xiaoping Lin; Fiona M Walter; Jane M Young; David J Barnes; Paul Mitchell; Bianca Brijnath; Andrew Martin; Jon D Emery
Journal:  BMC Cancer       Date:  2018-07-21       Impact factor: 4.430

10.  Timeliness of cancer care in a regional Victorian health service: A comparison of high-volume (Lung) and low-volume (oesophagogastric) tumour streams.

Authors:  Mwila Kabwe; Amanda Robinson; Yachna Shethia; Carol Parker; Robert Blum; Ilana Solo; Michael Leach
Journal:  Cancer Rep (Hoboken)       Date:  2020-10-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.